Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: KRAZATI
12.1 Mechanism of Action Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state that prevents downstream signaling without affecting wild-type KRAS protein. Adagrasib inhibited tumor cell growth and viability in cells harboring KRAS G12C mutations and resulted in tumor regression in KRAS G12C-mutated tumor xenograft models with minimal off-target activity. Adagrasib in combination with cetuximab had increased antitumor activity in some cell line-derived and patient-derived KRAS G12C-mutant CRC tumor xenograft models compared to adagrasib or cetuximab alone.
Contraindications
9 documented side effects by frequency
5 Reddit threads analysed for ADAGRASIB
Overall Sentiment
Mixed
Comparison Threads
5
Avg Post Score
21 upvotes
Most discussed side effects in community
Threads directly comparing ADAGRASIB to other medications
Hi folks, If you’ve been following $ATYR on Reddit, Stocktwits, or X, you’ve seen a sharp uptick in negative posts, “insider” sounding comments, and dramatic price targets lately. Familiar faces of biotech short selling have weighed in - bringing sponsored short reports, viral “expert” posts, and a
BridgeBio Oncology Therapeutics, Inc. (BBOT) – Investor Summary Overview BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotech company focused on precision cancer therapies targeting RAS-driven malignancies. Following the August 2025 business combination with Helix Acquisition Corp. II
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
0 available comparisons
No comparisons yet.
Dosage Forms
Tablet
Route
Oral